Ventus Therapeutics tacks on $100M to take on ‘undruggable’ disease targets April 8, 2021 Auto Bot BioPharma, biopharma nl, inflammation, investing, Massachusetts, Pharma, waltham 0 RA Capital led Ventus Therapeutics’ Series B financing, which the startup will use to develop its pipeline of medicines for “undruggable” disease targets. CEO Marcelo Bigal said the cash also gives Ventus the flexibility to consider an IPO.